Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16875750 | 0.89 | TTR (0.41) | AKR1C3AKR1C2CTSARARBALPL | |
| SCHEMBL3659205 | 0.83 | DHODH (0.46) | AKR1C3AKR1C2ALPL | |
| SCHEMBL16195521 | 0.73 | DHODH (0.52) | AKR1C3AKR1C2JAK2PTGS2GRM2 | |
| SCHEMBL3641384 | 0.71 | ALDH1A1 (0.53) | AKR1C3AKR1C2KDM1AHDAC1JAK2 | |
| SCHEMBL2262047 | 0.71 | KDM1A (0.59) | AKR1C3AKR1C2KDM1AHDAC1JAK2 | |
| SCHEMBL408325 | 0.71 | KDM1A (0.42) | AKR1C3AKR1C2KDM1AHDAC1JAK2 | |
| SCHEMBL3072305 | 0.70 | HDAC1 (0.46) | AKR1C3AKR1C2KDM1AHDAC1JAK2 | |
| SCHEMBL18397597 | 0.70 | AKR1C3 (0.64) | AKR1C3AKR1C2JAK2HDAC6MRGPRX4 | |
| SCHEMBL3660906 | 0.70 | DHODH (0.43) | AKR1C3ALPL | |
| SCHEMBL14931591 | 0.69 | TTR (0.39) | AKR1C3AKR1C2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | AKR1C3 1622/4885AKR1C2 3111/4885KDM1A 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.